drugset / Trial / NCT02296853
Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.
Timeline
- Start
- 2014-12-22
- Primary completion
- 2015-04-17
- Completion
- 2015-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tenofovir alafenamide | Small molecule | 25 mg | Oral |